Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelarabine for Relapsed or Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma
NCT00005950Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2000
- Primary completion
- Oct 2004
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nelarabine in B-cell non-Hodgkin lymphoma, peripheral T-cell lymphoma (PTCL), sponsored by National Cancer Institute. Started Apr 2000; status: terminated.
02
Drugs
nelarabine
03
Conditions
B-cell non-Hodgkin lymphomaperipheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT00005950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005950.